semaglutide and seizures New Study Suggests May Reduce Epilepsy Risk in Type 2 Diabetes Association Between GLP-1 Receptor Agonist
Description
In this trial, subjects with T2D with ( N = 36) or without ( N = 19) upper gastrointestinal (GI) disease received oral semaglutide 3 mg once daily for 5 days followed by 7 mg for 5 days
References Ewertz M, Jensen MB, Gunnarsdttir K, et al
Please visit this site as we will be updating as and when research outcomes are released
Why is a Safe Wegovy Dosage Guide Important
